Program Description & Educational Objectives
In this three-part activity, experts in the treatment of chronic pain discuss the latest information pertaining to the management of this condition. Highlights of this program include a succinct overview of the pathophysiology and characteristics of chronic pain, practical considerations for individualizing therapy in this patient population, and potential strategies to optimize the management of chronic pain by improving treatment adherence, enhancing patient-practitioner communication, and minimizing medication misuse or abuse.
Upon completion of this activity, participants should be better able to:
- Describe the underlying pathophysiological properties and characteristics of the various types of chronic pain
- Develop and implement treatment strategies for the management of individual patients with chronic pain after careful consideration of their pain etiology and characteristics, as well as analysis of recent clinical trial data
- Propose effective strategies for the optimization of the management of chronic pain by improving treatment adherence and patient communication, and minimizing medication misuse or abuse
Target Audience
This activity has been designed to meet the educational needs of primary care physicians and other clinicians involved in the management of patients with chronic pain.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: May 03, 2010 - May 02, 2011
Time to Complete: 45 minutes
Faculty & Disclosure
Course Director and Interviewee
Perry G. Fine, MD
Professor, Department of Anesthesiology
Pain Research Center
School of Medicine
University of Utah
Salt Lake City, Utah
Perry G. Fine, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Cephalon, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Advisory Board for Ameritox, Ltd.; Cephalon, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; King Pharmaceuticals Inc.; Meda Pharmaceuticals Inc.; Neuroadjuvants, Inc.; PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; and Wyeth Pharmaceuticals Inc.
Other Financial or Material Support from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Interviewees
Charles Argoff, MD
Professor of Neurology
Albany Medical College
Director of the Comprehensive Pain Program
Albany Medical Center
Albany, New York
Charles Argoff, MD,
has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Eli Lilly and Company; Endo Pharmaceuticals; Forest Laboratories Inc.; and Pfizer Inc.
Speakers Bureau participant with Eli Lilly and Company; Endo Pharmaceuticals; Forest Laboratories Inc.; King Pharmaceuticals Inc.; Pfizer Inc; and PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Advisory Board for Eli Lilly and Company; Forest Laboratories Inc.; Grünenthal; Jazz Pharmaceuticals, Inc.; NeurogesX, Inc.; Pfizer Inc; sanofi-aventis; Shire; and Solvay Pharmaceuticals, Inc.
Steven D. Passik, PhD
Associate Professor of Psychiatry
Weill Medical College of Cornell University
Associate Attending Psychologist
Memorial Sloan-Kettering Cancer Center
New York, New York
Steven D. Passik, PhD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Cephalon, Inc.; Eli Lilly and Company; King Pharmaceuticals Inc.; Ligand Pharmaceuticals Incorporated; and PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Grant/Research Support from Cephalon, Inc. and Ligand Pharmaceuticals Incorporated.
Speakers Bureau participant with Cephalon, Inc.; Eli Lilly and Company; King Pharmaceuticals Inc.; Ligand Pharmaceuticals Incorporated; and PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
CME Reviewer
Daniel J. Clauw, MD
Professor of Medicine, Division of Rheumatology at the University of Michigan
Director, Chronic Pain and Fatigue Research Center
Director, Michigan Institute for Clinical and Health Research
Associate Dean for Clinical and Translational Research
University of Michigan Medical School
Ann Arbor, Michigan
Daniel J. Clauw, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca, Ltd.; Cypress Bioscience, Inc.; Eli Lilly and Company; Forest Laboratories Inc.; Pfizer Inc; and Pierre Fabre Pharmaceuticals Inc.
Credit Designation
Mr. Pierre Lavalard, MBA
Associate Director
Office of CME
Department of Medical Education
University of Michigan Medical School
Ann Arbor, Michigan
Mr. Pierre Lavalard, MBA,
currently has no financial interests/relationships or affiliations in relation to this activity.
Content Director
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education, Inc.
Kirk A. Tacka, PhD,
currently has no financial interests/relationships or affiliations in relation to this activity.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and PVI, PeerView Institute for Medical Education. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
The University of Michigan Medical School designates this educational activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from 
